Price T Rowe Associates Inc Edgewise Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 23,086 shares of EWTX stock, worth $602,313. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,086
Previous 16,424
40.56%
Holding current value
$602,313
Previous $300,000
38.67%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding EWTX
# of Institutions
144Shares Held
96.7MCall Options Held
45.7KPut Options Held
5.3K-
Orbimed Advisors LLC San Diego, CA15MShares$392 Million6.52% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$232 Million2.42% of portfolio
-
Novo Holdings Hellerup, G76.34MShares$166 Million8.16% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$157 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$152 Million1.4% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.65B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...